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OsteoarthritisObjective: Current orthopedic therapies, aimed solely at symptomatic control, are unable to restore the
cytokine imbalance that produces the hallmark clinical profile of osteoarthritis. While a myriad of chem-
ical factors in the cytokine network stimulate local joint inflammation and pain, Interleukin 1 (IL-1) is
widely recognized as a key offender and a potential therapeutic target. The purpose of this article is to
describe a novel, on-site, point of service process (ArthrokinexTM) to induce Interleukin 1 Receptor
Antagonist Protein (IL-1-Ra or IRAP) from whole blood aimed at inhibiting the destructive intra-
articular effects of IL-1.
Methods: 53 patient charts were included in this retrospective chart review study. Venous blood from the
selected participants had been harvested and centrifuged to isolate Platelet Rich Plasma and Platelet Poor
Plasma. These layers were extracted and incubated for 30 min in a specialized syringe containing medical
grade concentrator beads. After centrifuge filtration, the supernatant containing IL-1-Ra was extracted.
Anti-inflammatory (IL-1-Ra, IL-10) and pro-inflammatory (TNF a, IL-1 b) cytokines of baseline whole
blood were compared to the conditioned serum following quantification using ELISA.
Results: On average, a 32-fold increase (baseline, 550 pg/mL; post conditioning 17,537 pg/mL) in IL-1-Ra
concentration was observed after the brief interaction of blood with the concentrator bead surface. IL-1-
Ra, if present in concentrations that are 10–100 times higher than IL-1b, will block the interaction of IL-1b
with cell surface receptors. At these increased concentrations, ArthrokinexTM induced IL-1-Ra joint injec-
tions produce an IL-1-Ra to IL-1b ratio of 999:1. Post conditioning levels of IL-1b and TNF awere not clin-
ically significant.
Conclusion: The ArthrokinexTM blood conditioning process has the ability to rapidly induce IL-1-Ra with-
out increasing the pro-inflammatory cytokine profile.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The poorly understood, multi-factorial pathogenesis of
osteoarthritis (OA) provides a significant challenge to treat the
estimated 27 million people in the US [1] affected by the progres-
sively debilitating disease. Articular cartilage destruction, sub-
chondral bone remodeling and synovitis are the chief causes of
the clinical manifestation of OA, which include pain, swelling,
and stiffness of the affected joint. Axiomatically, these symptoms
can pose a dramatic hindrance on daily activities depending on
severity. Analgesic drugs, nonsteroidal anti-inflammatory drugs
(NSAIDs) and intra-articular (IA) corticosteroid injections are thecurrently recommended pharmacologic interventions for knee OA
[2]. Given the limited scope and effectiveness of these treatment
options aimed solely at symptomatic control of the disease, many
patients are forced to undergo surgery. Regenerative therapies
including platelet rich plasma and mesenchymal stem cells, are
on the rise despite conflicting evidence of supportive data. Early
data indicated the potential musculoskeletal benefits and cost
effectiveness of platelet rich plasma (PRP) injections. The majority
of trials have failed to provide evidence for the increased use of PRP
therapy [3]; however it is difficult to pinpoint if this is due to the
actual treatment regimen or the lack of standardized protocols,
platelet separation techniques and outcome measures. Interest-
ingly, a recent systemic review and meta-analysis reported PRP
IA injections are significantly superior to placebo and hyaluronic
acid for the treatment of knee OA (all other outcomes were
excluded) [4]. Despite inconsistent results, the market value of
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recent studies are beginning to emerge that reveal the potential
for autologous adipose tissue derived mesenchymal stem cells,
albeit to a much smaller degree than PRP, for the treatment of
OA [6]. The need for an out-patient, on-site, point of service, low
cost symptom relieving and possibly chondroprotective drug is
evident given the already high prevalence of arthritis in the US,
which is expected to increase to nearly 67 million people by the
year 2030 [7], the significant financial burden to the patient
($703/year) and insurer ($3080/year) [8] and the lack of effective
non-surgical options.
A recently improved knowledge of the molecular mechanisms
underlying this disease has led to the exploration of biotherapeutic
strategies. One approach that holds promise is the inhibition of
interleukin-1b (IL-1 b), a major cytokine promoting the catabolic
activity associated with OA affected joints [9]. Attur et al. [10]
reported the presence of biologically active IL-1b in OA-damaged
cartilage providing the rationale to explore blockade of this mole-
cule as a target to facilitate cartilage repair and potentially reverse
degradation. Different methods to specifically inhibit Interleukin 1
(IL-1) have been tested. Briefly, those include the application of sol-
uble IL-1 receptors, monoclonal antibodies against IL-1 or IL-1
receptor 1, blocking the formation of active IL-1b, gene therapy,
and the application of IL-1 receptor antagonist protein (IL-1-Ra)
[9], which serves as the focus of this investigation. It is unclear
which method is most effective; however, the success of three
commercially available IL-1-Ra products (recombinant AnakinraTM,
autologous OrthokineTM and ArthrexTM) led to the development of
our novel IL-1-Ra formulation process. The primary purpose of this
investigation was to test our hypothesis that our on-site, point of
service, minimal manipulation processing of whole blood would
induce sufficient IL-1-Ra levels and IL-1-Ra:IL-1b block ratios. Sec-
ondary outcomes were twofold: (1) to ensure the ArthrokinexTM
process did not increase the concentration of anti-inflammatory
cytokines (TNF-a and IL-1b) and (2) to evaluate cytokines levels
in the serum samples after being stored at 20 C for at least one
year.2. Materials and methods
2.1. Study design
This was a retrospective chart review/proof of concept investi-
gation aimed to quantify the ability of the ArthrokinexTM process
to enhance IL-1-Ra in whole blood. All aspects of the study protocol
were extensively reviewed and approved by IntegReview Institu-
tional Review Board (IRB) as being considered exempt from requir-
ing IRB approval as it met all requirements outlined in 45 CFR
46.101(b)(4), specifically (1) the research involves only the collec-
tion or study of pre-existing data, documents, records, pathologic
specimens or diagnostic specimens and (2) the information will
be recorded in such a manner that the subjects cannot be identi-
fied, directly or through identifiers linked to the subjects.2.2. Participants
Existing charts were reviewed and a total of fifty three (53)
patient charts met all inclusion criteria for this analysis: age
>21 years, chronic OA for at least 3 months, patients were diag-
nosed with OA according to the American College of Rheumatology
(ACR) criteria, radiographic evidence of OA andP4 pain grade (on
a numeric scale of 1–10). Exclusion criteria included: patient charts
of those in generally poor health, pregnant or breast feeding, drug
dependent (chronic opioid use, alcohol, etc.), undergone surgery or
treatment of the affected joint within the last 3 months, lacked themental ability to understand the treatment plan, systemic disease
of the musculoskeletal system, bone cancer, metastasis or tumor-
like lesions in the immediate proximity to the treated joint, frac-
ture in the last 3 months, acute bacterial infection, blood clotting
disorders, major psychiatric disease requiring therapy, and contin-
uous corticoid or NSAID therapy due to other diseases. Informed
consent was obtained from each participant and all work was per-
formed in accordance with The Code of Ethics of theWorld Medical
Association (Declaration of Helsinki).2.3. Processing of whole blood (ArthrokinexTM)
Using aseptic techniques, 60 mL whole blood from the median
cubital vein of fifty three (53) participants was harvested into a
sterile 60 mL syringe containing 3 mL of anticoagulant citrate dex-
trose (ACD) solution and centrifuged (3200 rpm, 15 min). The
resultant Platelet Rich Plasma (PRP) and Platelet Poor Plasma
(PPP) were then extracted and the remaining layers, containing
buffy coat and erythrocytes, were discarded. Both the PRP and
PPP were transferred to a specialized, closed-system, centrifuge
tube containing medical grade concentrator beads, mixed and
allowed to incubate for 30 min at ambient temperature. After the
short incubation period, centrifuge filtration (2000 rpm, 3
1/2 min) through a sterile 0.45 lm filter was completed and the
resulting sterile filtrate was slowly drawn into 1 mL syringes. The
1 mL syringes could be used immediately for intra-articular injec-
tion or stored at 20 C for future use.2.4. Biomarker assays
The primary outcome of measuring IL-1-Ra (pre- and post-
conditioning) was achieved by using the highly sensitive, commer-
cially available quantitative sandwich enzyme-linked immunoas-
say technique (R&D Systems, Quantikine ELISA; Minneapolis, MN,
USA. The manufacturer reports this kit, when run in accordance
with standard Quantikine protocols, to be extremely sensitive
(minimum detectable dose ranged from 2.2 to 18.3 pg/mL), specific
(no significant cross-reactivity or interference was observed), pre-
cise (intra- and inter-assay CVs were 3.7% and 6.7%) and linear (all
diluted samples fell with the dynamic range of the assay). Since
sample concentrations were expected to fall outside the range of
provided standards, serum was diluted 100 fold by adding 5 ll of
sample to 495 ll of calibrator diluent. Resulting concentrations
were calculated by subtracting the average zero standard optical
density and log transforming IL-1-Ra concentrations versus the
log of the optic density on a linear scale, and the best fit line deter-
mined by regression analysis. IL-1-Ra concentrations were only
accepted if the standard curve correlation coefficient (r) reached
0.99 and the CV of each sample was under 20%.
As a secondary outcome, serum levels (pre- and post-
conditioning) of pro-inflammatory (TNFa, IL-1b) cytokines and
another anti-inflammatory cytokine (IL-10) were measured sepa-
rately using ELISA. All kits reported comparable sensitivity, speci-
ficity, precision and linearity as described above. Similar to IL-1-
Ra, all kits were run in accordance with standard Quantikine
protocols.2.5. Statistical analysis
SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Wilcoxon signed rank test were performed to
analyze the statistical difference between baseline and post-
processing cytokine levels. All results shown are the mean ± SEM
of two or more experiments.
Table 2





Fold increase P value
IL-1-Ra 549.6 ± 52.6 17,537 ± 1234 31.9 <0.0001
IL-1 b 7.3 ± 0.8 17.5 ± 2.0 2.4 <0.0001
IL-10 24.9 ± 2.7 31.7 ± 4.8 1.3 <0.001

















Fig. 1. Autologous conditioned serum (ArthrokinexTM) produces a favorable
cytokine profile by shifting the anti-inflammatory to pro-inflammatory ratio.
Enhanced concentration of IL-1-Ra has the potential to block the destructive effects
of IL-1b.
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3.1. Participant characteristics
Of the 53 participants, 25 men and 28 women were included.
The mean age was 59.8, ranging from 25 to 85 years. According
to the World Health Organization guidelines, 16 of the 53 (30%)
participants were classified as overweight (BMIP 25 kg/m2) and
30 participants (57%) are classified as obese (BMIP 30 kg/m2). Of
the 30 obese patients, 21 fall into the category of class I obesity
(BMI 30–34.99 kg/m2), 6 were classified as class II obese (BMI
35–39.99 kg/m2) and 3 were characterized as class III obese
(BMIP 40 kg/m2) (Table 1).
3.2. Primary outcome: ArthrokinexTM process induced IL-1-Ra levels
Autologous conditioned serum resulted in a markedly increased
induction of ArthrokinexTM-derived IL-1-Ra (17,537 ± 1234 pg/mL)
(Table 2). These values are comparable to IL-1-Ra levels produced
by OrthokineTM [11] and ArthrexTM [12]. On average, after the short
30 min incubation period, a 32 fold increase in IL-1-Ra was
observed between baseline and post-ArtrhokinexTM serum. IL-1-Ra
levels increased by at least a factor of 10 in 50 (out of 53) serum
samples. Furthermore, 5 samples obtained IL-1-Ra levels that
increased at least 20 times from baseline, 14 samples that increased
at least 30 times from baseline, 11 samples that increased at least
40 times from baseline and 13 samples that increased at least
50 times from baseline. One sample increased by a factor 120,
representing the highest increase of IL-1-Ra observed. This robust
and rapid increase in IL-1-Ra synthesis resulted in a mean serum
IL-1-Ra to IL-1b ratio of 999.0 (Fig. 1).
3.3. Secondary outcomes: IL-10, TNF-a, IL-1b
In addition to the 32 fold increase in IL-1-Ra, a statistically sig-
nificant increase in the anti-inflammatory Interleukin 10 cytokine
(p < 0.001) was observed. Despite this statistical significance, the
clinical significance of this increase is negligible. A statistical
increase was also observed in the pre and post-ArthrokinexTM levels
of IL-1b and TNF a (Table 2); however, similar to IL-10, these
increases are not clinically significant.
3.4. Storage of autologous conditioned serum
Following our novel conditioning process, approximately
6–12 mL of concentrated IL-1-Ra rich serum is extracted. In order
to test the storage capacity of ArthrokinexTM, a small, separate
subset of patients’ (n = 21) conditioned sera that had been stored
at 20 C for at least one year was analyzed using ELISA. Mean
IL-1-Ra levels remained markedly elevated (16,167 ± 109 pg/mL)
and were similar to mean levels of IL-1-Ra observed soon after pro-
cessing. A similar trend was observed in each of the additional
cytokine levels measured in this investigation (IL-10,
31.9 ± 4.1 pg/mL; IL-1b, 42.5 ± 3.7 pg/mL, TNFa, 13.1 ± 0.7 pg/mL).Table 1
Patient demographics and clinical characteristics.
N 53
Male/female 25/28
Mean age (range) 59.8 (25–85)
BMI classification
Overweight (BMIP 25 kg/m2) 16/53 (30%)
Obese Class I (BMI 30–34.99 kg/m2) 21/53 (40%)
Obese Class II (BMI 35–39.99 kg/m2) 6/53 (11%)
Obese Class III (BMIP 40 kg/m2) 3/53 (6%)4. Discussion
The primary aim of this investigation was to determine the
capacity of the ArthrokinexTM conditioning process to induce
synthesis of IL-1-Ra from a patient’s whole blood. The desired
therapeutic effect of ArthrokinexTM is facilitated by the ability of
IL-1-Ra to limit the destructive inflammatory intra-articular
actions of IL-1b. Supranormal levels of IL-1b and TNFa, mainly pro-
duced by activated synoviocytes, mononuclear cells and articular
cartilage, drive the catabolic response and augment the pathogen-
esis of OA by stimulating release of other cytokines (IL-8, IL-6 and
nitric oxide) and prostaglandin E2. Additionally, IL-1b and TNFa
can increase their own production through autocrine signaling
which could further shift the equilibrium between IL-1b and
IL-1-Ra. All of these cytokines diffuse into the synovial fluid and
promote cartilage matrix degradation [13].
Consistent with previous studies designed to physico-
chemically induce anti-inflammatory cytokines [11,14,15], our
novel process provides sufficient levels of IL-1-Ra to competitively
inhibit IL-1b [15]. IL-1-Ra, if present in concentrations that are 10–
100 times higher than IL-1b, will block the interaction of IL-1bwith
cell surface receptors as well as soluble IL-1R type 2 [16]. The vol-
ume of the synovial fluid in an OA-affected knee increases to
approximately 13.6 mL [17] and contains 34 pg (2.5 pg/mL) of IL-
1b [18]. All serum levels in this trial exceeded the 100:1 threshold
so it is therefore reasonable to conclude that ArthrokinexTM can
consistently produce IL-1-Ra levels that will inhibit IL-1b.
The capability of IL-1-Ra to treat knee OA symptoms is con-
firmed in some [14,15], but not all [19] clinical trials. The largest
trial (n = 376) conducted by Baltzer et al. [14], was designed to
compare the clinical effectiveness of intra-articularly administered
IL-1-Ra (OrthokineTM) to hyaluronan (HA) and saline. Patients in
each group had two appointments with a physician per week for
three consecutive weeks. Patients in the saline and HA group
received a total of three injections and the patients in the IL-1-Ra
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patients showed significant improvements in all outcome mea-
sures compared to HA and saline-treated patients. Certainly, the
slightly different treatment regimens among groups should be con-
sidered; however, this preliminary study provides evidence for the
efficacy of intra-articular administration of IL-1-Ra as a treatment
strategy to combat the immobilizing effects of knee OA. Previously,
Yang et al. [15] reported a superior biological response elicited by
OrthokineTM compared to physiological saline in the treatment of
knee OA. Despite the comparable improvement on the WOMAC
in patients treated with OrthokineTM and placebo, KOOS (Knee
Injury and Osteoarthritis Outcome Score) symptoms and sport
parameters were significantly improved in the treatment group.
Additionally, other clinical observations in OrthokineTM-treated
patients were consistently improved but were not statistically sig-
nificant. Ultimately, the authors concluded the use of OrthokineTM
cannot yet be recommended for the treatment of knee OA since
the primary outcome of the investigation, 30% improvement in
WOMAC between groups, was not met.
Surprisingly, several recent review articles [20–22] have
ignored the success of OrthokineTM, but instead focused solely on
the inability of AnakinraTM to provide symptomatic relief of KOA
that was significantly superior to placebo. In an open label ran-
domized, multicenter, double-blind, placebo-controlled trial
(n = 160), patients were divided into 3 groups and received a single
intra-articular dose of AnakinraTM (150 mg or 50 mg) or placebo
[20]. After 4 weeks, WOMAC global scores for all group improved
with a non-significant difference between placebo and AnakinraTM
50 mg and between placebo and AnakinraTM 150 mg. A statistically
significant improvement (p = 0.051) was approached between the
placebo group and the AnakinraTM 150 mg group in the WOMAC
pain sub-score on day 4. However, it is difficult to directly compare
this trial to previous findings since only a single injection was
administered. Additional trials are needed to determine whether
repeated injections deliver therapeutic levels of IL-1-Ra to reduce
pain.
Several clinical human trials have reported improved clinical
outcomes of patients with muscle [23] and ligament injury
[24–28] as well as spinal disorders [29] following IL-1-Ra treat-
ment. Of particular interest, Darabos et al. [26] compared IL-1b
levels in the synovial fluid (SF) of 10 patients treated with IL-1-Ra
to 10 patients treated with placebo (physiological saline) following
ACL reconstruction surgery. Surgery caused an immediate elevation
of synovial fluid concentration of IL-1b levels in almost all patients
(19 of 20). After 10 days, patients treated with IL-1-Ra had concen-
trations that were equal to or below the concentration in a normal
knee and statistically lower than placebo. The authors concluded
that the dramatic decrease in IL-1b facilitated by IL-1-Ra applica-
tion could augment the ACL healing process. The same authors con-
firmed these results in a larger trial (n = 62) and observed several
postoperative outcomes associated with IL-1b concentrations
[27]. The most important finding was the significant reduction in
bone tunnel widening in autologous conditioned serum (ACS) trea-
ted patients at 6- and 12 months. Treated patients had significantly
fewer joint effusions and performed better on functional tests at
6 months and had significantly greater range of motion at
12 months. Patient-administered outcomes (WOMAC and IKDC)
were significantly improved in ACS-treated and placebo-treated
groups; however, patients treated with ACS reported consistently
lower pain scores and significantly improved WOMAC stiffness
scores (p = 0.047) compared to placebo.
Treatment of OA continues to be a challenge for clinicians and
investigators. As the population continues to age, a greater per-
centage of the population will likely develop OA and require surgi-
cal intervention unless a disease modifying drug is developed. To
date, the Osteoarthritis Society International (OARSI) [30] andEuropean League against Rheumatism [31] recommend acetami-
nophen as the first choice of oral analgesics to treat mild-
moderate knee OA, and if successful, should be used as the pre-
ferred long-term analgesic due to its efficacy, relative safety and
low cost. However, the evidence suggests that NSAIDs are superior
to acetaminophen for improving knee pain in people with OA [32]
and should be administered to patients who do not respond to
acetaminophen [30,33–35] or as an initial therapy option for
patients with moderate to severe pain [2,36]. Despite the superior
clinical response, NSAIDs should be used with caution due to the
well documented serious gastro-intestinal, renal and cardiovascu-
lar toxicities [37] including the FDA warnings about stroke and
myocardial infarction. Another recommended treatment option
includes the short-term use of IA corticosteroid injections [35];
however, similar to NSAIDs treatment, serious potential side
effects of long term administration abound [38]. Since knee OA is
a chronic disease, these short term treatment options highlight
the significant unmet need for a disease-modifying OA drug that
does not have any major side effects.
5. Conclusions
Our novel process to induce extremely high levels of the potent
receptor antagonist for IL-1 requires a short incubation time to
allow same day, point of care service to patients, utilizing a closed
loop system to reduce the risk of contamination, and does not
introduce any additional chemicals to the biotherapeutic product.
Extremely high levels of IL-1-Ra are consistently achieved without
augmenting key pro-inflammatory cytokines. Additionally, it is
relatively inexpensive and can be safely stored without degrading
IL-1-Ra or compromising the IL-1-Ra:IL-1b block. A large, well-
designed, randomized clinical trial is needed to assess the symp-
tom relief and chondroprotective effects of IL-1-Ra. Meanwhile,
the ArthrokinexTM conditioning process offers an alternative, point
of service molecular approach to rapidly induce IL-1-Ra which
has the potential to provide therapeutic benefit in the treatment
of mild to moderate OA.
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